Traveling with HIV Authors: Victor Daniel Miron, Lorenzo Rabbi, Sai Keertana Devarapalli, Ana Fidji Glaría Campo, Justyna Kowalska, Victor Daniel Miron, Victor Daniel Miron, Lorenzo Rabbi, Justyna Kowalska Published: 2026 ABSTRACT International travel is increasingly common, and it remains a clinical context in which preventable morbidity may occur if not adequately addressed through a comprehensive pre-travel consultation. This article provides a structured, evidence-informed framework for counseling people living with human immunodeficiency virus (HIV) who travel internationally, emphasizing the need for individualized assessment and proactive risk mitigation. We outline key domains relevant to travel health in people living with HIV, including legal and structural barriers, general health evaluation, vaccination planning, malaria prevention, sexual health, and strategies for managing expected and unexpected events during travel. Persistent HIV-related entry, stay, and residence restrictions in some countries may influence itinerary planning, disclosure, and access to healthcare abroad. From a clinical perspective, the cornerstone of safe travel is sustained viral suppression on antiretroviral therapy, with careful planning to ensure uninterrupted medication supply, adherence across time zones, and preparedness for loss or theft of medications. Drug-drug interactions are an important consideration, particularly when prescribing malaria chemoprophylaxis or antibiotics. Vaccination strategies should include routine and travel-specific immunizations, with attention to immune status, and the possibility of reduced immunogenicity requiring serological assessment or additional vaccine doses to obtain optimal response. Travel may increase sexual risk-taking and exposure to sexually transmitted infections (STIs), warranting targeted counseling on prevention, post-exposure strategies, and access to testing and treatment. Destination-specific precautions, such as malaria prevention, must combine rigorous mosquito avoidance measures with appropriate chemoprophylaxis compatible with antiretroviral therapy (ART) regimens. Overall, HIV-informed travel counseling should be considered a standard component of comprehensive HIV care, integrating medical, pharmacological, behavioral, and structural considerations to support safe travel and reduce avoidable complications. Introduction This article aims to provide a broad perspective for travelers living with human immunodeficiency virus (HIV). International travel is best undertaken with meticulous and personalized planning, and many of the principles of safe travel are universally applicable, regardless of whether or not a person is living with HIV [1]. However, not all travel-related circumstances can be anticipated beforehand, and certain particularities should be taken into account for people living with HIV, even in the context of modern antiretroviral therapy and near-normal life expectancy [2]. The cornerstone of safe travel is being on effective antiretroviral therapy, together with sufficient medication supply attention to adherence, and a clear plan for managing treatment interruptions and drug-drug interactions [3]. However, given the accessibility of global transportation and demands of modern lifestyle, a pre-travel medical consultation is rarely considered by most people, even though it is a key opportunity to identify individual risks and reduce travel-associated morbidity. In addition, travelers living with HIV may encounter structural barriers, including persistent HIV-related entry, stay, or residence restrictions in some countries, which can influence travel planning, disclosure, and access to care abroad [4]. The expanding mobility of people living with HIV, together with the complexity of contemporary travel itineraries, makes it increasingly important to frame travel health within an HIV-specific risk assessment model. Although viral suppression has transformed HIV into a chronic manageable condition, immune status, comorbidities, polypharmacy, and regional epidemiology may intersect in ways that significantly influence travel-related risk [2, 3]. Evidence from travel medicine surveillance networks indicates that, among infectious diseases, an important proportion may be preventable infectious diseases, especially when pre-travel counseling is absent or incomplete [5, 6]. For people living with HIV, this underscores the importance of structured discussion around vaccination strategies, malaria prevention, medication planning, and broader health considerations, not as isolated interventions, but as integrated components of personalized risk mitigation. Establishing this context is essential to understanding why HIV-informed pre-travel evaluation should be considered standard practice rather than optional care. Travel may also change sexual behaviors and increase the risk of sexually transmitted infections (STIs), with studies reporting higher rates of new partnerships and reduced condom use while abroad in some groups [7, 8]. For people living with HIV, incident STIs can cause morbidity and may increase HIV transmissibility in the absence of sustained viral suppression. Counseling should therefore include STI prevention and a plan for timely testing during travel and upon return. This is also particularly relevant for HIV prevention, where effective pre-exposure prophylaxis (PrEP) can significantly decrease the risk of HIV acquisition through sexual contact [9, 10]. Here we propose solutions and considerations for both expected and unexpected scenarios related to traveling with HIV or for individuals at risk of acquiring HIV. This manuscript has been developed by HIV specialists with expertise in infectious diseases and travel medicine to provide a structured, evidence-informed framework for international travel for people living with HIV. It addresses key domains including legal considerations and travel restrictions, general health assessment and individualized recommendations, pre-travel vaccination, malaria prevention, sexual health risks during travel, and strategies for pre- and post-travel management. Legislation and traveling with HIV In most countries, living with HIV does not impact a person’s ability to travel from a legislative point of view. However, a substantial number of countries and territories have entry restrictions for extended stays or permanent settlement. Because attitudes and regulations concerning people living with HIV vary globally, it’s important to research each destination carefully. If travelers are uncertain about the local policies or the safety of disclosing HIV status, they should seek guidance from the local embassy or consulate. Planning ahead can help ensure a smooth travel experience. Before traveling, one must ensure that the country doesn’t restrict the entry, stay, or residence of people living with HIV. These restrictions could include visa limitations, refusal of entry, mandatory disclosure, or denial of residence permits. Despite ongoing advocacy and human rights considerations, only 83 out of 201 countries have no restrictions related to travelling for people living with HIV [4]. Thirty-three countries, including, Canada, Hungary and Australia, have partial restrictions and 16 countries, including Russia, Egypt and Malaysia, have severe restrictions [11]. Some restrictions may indirectly affect people living with HIV, especially from key populations such as men who have sex with men (MSM), people who use psychoactive substances, or sex workers, due to criminalization of same-sex relationships, possession of small amounts of drugs for own use, or transactional sex. Travelers should consult resources such as the HIV Justice Network, which maintains a global database of HIV criminalization laws [12]. Up to date information on country-specific HIV-related travel restrictions can be accessed via the UNAIDS travel restriction database (https://travelrestrictions.unaids.org/). Since laws and restrictions can change without notifications, it is therefore advised to stay up to date with these resources before the trip to avoid travelling delays, legal or safety issues. General health considerations for travelers living with HIV Travel is generally considered safe for people living with HIV who are on effective antiretroviral therapy (ART) and have a CD4 lymphocyte count above 200 cells/µL [3]. If the traveler cannot postpone the trip and must travel with a CD4 count below 200 cells/µL, extra precautionary measures need to be taken. Travelers may consider wearing masks (FFP2, N95, or other types) at the airport, in crowded environments and in closed indoor spaces, as an additional precautionary measure. The travelers should reduce exposure to infection, frequently disinfect their hands, and prioritize open air venues with fewer people. As for any other traveler, it is recommended to carry a small travel health kit with essential medications, such as anti-diarrheal medications, antipyretics, oral rehydration salts and a basic first aid kit. Prophylaxis for opportunistic infections should be given as per standard guideline practice, i.e., co-trimoxazole for Pneumocystis jirovecii pneumonia and toxoplasmosis or azithromycin for Mycobacterium avium complex, as part of routine clinical care and based on CD4 level. Initiating any prophylactic beyond those already prescribed as per guidelines is not recommended [3]. Sun protection (using high-sun protection factor sunscreens, wearing protective clothing, seeking shade) is crucial for every traveler, but especially for those using co-trimoxazole and doxycycline, as these medications are associated with extreme photosensitivity and can lead to severe sun burns [13]. Specific recommendations for travelers living with HIV Consulting with one’s HIV specialist at least 4–8 weeks before travel is highly recommended. People living with HIV are encouraged to discuss travel itinerary and to plan medication needs in advance. This allows the doctor to consider the length of the trip, potential risk factors at the destination, vaccination requirements and quantity of ART and other medications needed. Doctors can review the patient’s immunological status, co-morbidities and history of opportunistic infections to discuss specific vulnerabilities, prescribe alternative medications or prophylactics and administer relevant vaccinations. Telemedicine follow-ups, which gained international prominence during the COVID-19 pandemic, represent an invaluable tool for continuous care while abroad [14]. Virtual consultation gives the patient the possibility to receive quick and trusted advice in case of unexpected events like missed doses, side effects, or acute illness while ensuring continuity of care. When planning for medications, it is advised that people living with HIV carry a full supply of ART and other prophylactics for the entire duration of the trip with an additional 1 or 2 weeks’ worth to account for delays or unexpected events. All medications should be packed in carry-on luggage for easy access and kept in its original packaging to avoid issues at security and customs controls. The HIV specialist should provide a written medical note stating the commercial name and active ingredients, the dosing schedule and the medical justification for carrying the medication. Medical justification can be important for customs in countries with strict pharmaceutical regulations. Medications should never be rationed, split, or skipped, even temporarily, as this increases the risk of viral resistance and subsequent treatment failure. It is important to explain to patients that after stopping ART, the virus can emerge quickly, within the first couple of weeks, creating a risk of transmission [15]. Although stopping ART for a few days would not be immediately harmful, the patient can experience some symptoms, such as fatigue or weakness. Furthermore, depending on the duration of interruption, viral replication in the presence of suboptimal residual antiretroviral drug levels can significantly increase the risk of selecting resistance mutations. A long-term treatment interruption will always result in the decline of CD4 cell count and lead to disease progression and development of opportunistic infections [16]. For many travelers, changes in the time zones during travel can pose a significant problem. In the current era of ART with a high genetic barrier to resistance, taking ART at a convenient time in the new time zone, rather than strictly adhering to the home schedule, may minimize dosing errors and improve adherence without compromising efficacy. Patients should consult with their healthcare provider to guide their dosing schedule pre-travel and help adjust to new local time. In case of lost or stolen medication, one must find a local hospital or clinic to refill their prescription as soon as possible. In this case, a temporary, emergent ART regimen switch may be required based on what is available in that country. Access to specific ART varies globally, but many HIV clinics can provide a one-month emergency supply [17]. Therefore, people living with HIV are advised to identify local HIV clinics or non-governmental organizations at destination before traveling. It is essential for people living with HIV to remember or write down the name of their ART medication, and to keep a physical or scanned copy of the medical letter at hand. Having a photo of drug package is usually very helpful as well. While most people living with HIV continue to receive standard oral ART, an increasing number are transitioning to long-acting injectable (LAI) regimens, namely cabotegravir plus rilpivirine or lenacapavir as add-on to an oral regimen. LAI regimens are a good option for travelers, since the person can travel in the periods between injections without the need to carry daily medications and can avoid the complexity of adjusting dosing times across time zones. Despite this, for people on LAI regimens, a treatment adjustment plan should be made before traveling, ideally moving the injection dose earlier if within the approved medication window, or considering oral bridging for short durations in case of anticipated long-acting dose delay. Pre-travel vaccination for people living with HIV Pre-travel vaccination constitutes a core component of preventive care strategies and it should be ensured that all vaccinations are up to date before departure. Generally, vaccines before travel remain the same for most individuals and could be divided into three categories: routine vaccines (e.g., diphtheria-tetanus-pertussis, influenza, etc.), vaccines specific for travel destinations (e.g., Japanese encephalitis or rabies) and vaccines required for entry (e.g., yellow fever) [18]. In people living with HIV, vaccine-related contraindications are generally limited and should be regarded as relative or temporary rather than absolute. The safety and immunogenicity of travel-specific vaccines should be weighted between patient’s immune status, necessity to travel and risk estimation for destination country or region. This is especially relevant for live attenuated vaccines (e.g., yellow fever, oral typhoid, measles, mumps, and rubella), which are dependent on the CD4 threshold and are generally contraindicated when CD4 is below 200 cells/µL or below 15% and in the presence of AIDS-defining conditions [3, 19, 20]. In such cases, travelers are strictly advised to take necessary precautions to avoid risk factors, which may include preventing mosquito bites for yellow fever, water and food safety measures for typhoid fever, and respiratory and contact precautions for measles, mumps, rubella or varicella [21]. For patients with contraindication for the yellow fever vaccination, a medical waiver letter might be necessary to enter the destination country. Inactivated, subunit, and recombinant vaccines are considered safe for people living with HIV regardless of the degree of immunosuppression. However, vaccine-induced immune responses may be suboptimal in individuals with low CD4 counts or uncontrolled viral replication, potentially necessitating additional doses or enhanced vaccination schedules. A detailed immunization history is essential to identify previously administered vaccines and determine the need for booster doses. In cases of uncertain or undocumented vaccination status, serological testing to determine immunity may be considered. To achieve adequate antibody responses, vaccines should ideally be administered when sufficient immune competence is present, generally defined by satisfactory CD4 cell counts and virological suppression. However, with imminent travel, this may not always be possible, and the general principle is that some protection (i.e., vaccinating despite an expected lower immune response) is better than no protection (i.e., deferring vaccination). When immune status or viral control is suboptimal, post-vaccination serological testing and booster doses may be required to ensure adequate long-term protection. Post-vaccination serologic testing is recommended to be performed one-two months after completing the Hepatitis A and B vaccine series [19]. Concomitant administration of multiple vaccines is frequently required in the pre-travel setting and is generally safe in people living with HIV, as in the general population. Inactivated, subunit, and recombinant vaccines may be administered simultaneously at different anatomical sites without compromising safety or immunogenicity. When two or more live-attenuated vaccines are indicated, they should either be administered on the same day or spaced by an interval of at least four weeks, in accordance with general vaccination principles [22]. Co-administration does not appear to increase the risk of adverse events in people living with HIV. However, attenuated immune responses may occur in individuals with advanced immunosuppression; consequently, accelerated vaccination schedules should generally be avoided and, when unavoidable, immune response assessment and additional booster doses may be warranted [3]. Table 1 summarizes travel vaccination recommendations for people living with HIV, highlighting the importance of immunization and outlining specific considerations in selected clinical scenarios. In the absence of specific contraindications or modifications, vaccination schedules should follow manufacturer/guidelines recommendations and those applied to the general population, as well as evidence-based recommendations specific for people living with HIV. Table 1Vaccines and their recommendation for travelers living with HIV [3, 19, 20]VaccineRecommendationRelevance for travel and special commentsA. Vaccines included in routine vaccination schedulesHepatitis B vaccineRecommendedTravel associated with sexual risk, medical procedures, occupational exposure.›› Check immunization history and anti-HBs levels for those who have been previously vaccinated.›› Check anti-HBs at least 4 weeks after completion of the regimen to confirm optimal response (≥ 10 mIU/mL) [3, 19].Hepatitis A vaccineRecommendedTravel to endemic regions, destinations with poor food hygiene, anticipated at-risk sexual activity.›› Check immunization history and HAV IgG levels for those who have been previously vaccinated.›› Check HAV IgG antibodies at least 4 weeks after completion of the regimen to confirm optimal response [19].MMR vaccineConditionally recommendedTravel to areas with measles outbreaks, or regions with high transmission.›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL.›› Check immunization history and measles (± mumps, ±rubella) IgG levels for those who have been previously vaccinated.COVID-19 vaccineRecommendedExposure in crowded areas/airports. Travel during periods of increased SARS-CoV-2 circulation. Association of risk factors for severe forms.Influenza vaccine (inactivated or recombinant)RecommendedTravel during influenza season. Exposure in crowded places/airports.Influenza vaccine (live-attenuated)ContraindicatedUse inactivated or recombinant influenza vaccine instead.RSV vaccineRecommendedTravel during RSV season for the elderly and/or those at increased risk of severe RSV infection.›› Age limit may vary depending on local vaccine approval.Pneumococcal vaccine (conjugate / polysaccharide)RecommendedHIV is a risk factor for severe pneumococcal disease, and represents an indication for vaccination.Hib vaccineConditionally recommendedTravel by people with chronic conditions with increased risk for Hib infection (asplenia, complement deficiency, immunosuppression, etc.).›› Not routinely recommended for HIV patients but applies to those with additional risk factors.Tetanus, diphtheria, and pertussis vaccine (DTaP, Td, Tdap)RecommendedTravelers at high risk of wounds/trauma.Travelers to areas with risk of diphtheria.Travelers to areas with pertussis outbreaks.›› For those already vaccinated, a previous dose administered within the last 10 years is generally still considered protective.Polio vaccine (inactivated)RecommendedTravel to countries with risk for polio or entry requirements.›› A booster dose administered during adulthood needed for those previously vaccinated during childhood.Meningococcal ACWY vaccine (MenACWY)RecommendedTravel to endemic areas of the “meningitis belt”, meningitis outbreaks or study travel. Travel by people with chronic conditions with an increased risk of meningococcal infection (see Hib).Meningococcal B vaccine (MenB)RecommendedTravel to meningococcal B infection outbreaks.Travel by people with chronic conditions with increased risk for meningococcal infection (see Hib).Varicella vaccineConditionally recommendedTravel to areas with chickenpox outbreaks, regions with transmission or prolonged community exposure.›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL.›› Varicella zoster-specific immunoglobulin can be used in people living with HIV who have contraindication to vaccination, following exposure to VZV [2].›› Check immunization history and varicella-zoster virus IgG levels for those who have been previously vaccinated.Zoster recombinant vaccineRecommendedEveryone 50 years or older; younger people living with HIV and a degree of immunosuppression.HPV vaccineRecommendedLong-term prevention. Recommended regardless of biological sex and especially for sexually active individuals.›› Recommended for persons aged 9–26 years. For selected people aged 27–45 who are inadequately vaccinated, shared clinical decision-making is recommended [19].Mpox vaccineRecommendedTravel to areas with transmission or anticipated exposure.›› Only the JYNNEOS (MVA-BN) vaccine is approved and indicated for people living with HIV regardless of their immune status.B. Travel-specific vaccinesRabies vaccineRecommendedTravel to endemic areas. Exposure to wild animals.›› Post-exposure prophylaxis (PEP) in unvaccinated individuals should include wound cleaning, human rabies immunoglobulin if needed, and a 4-dose vaccine schedule if CD4 ≥ 200 cells/µL or a 5-dose schedule if CD4 < 200 cells/µL or detectable viremia.Yellow fever vaccineConditionally recommendedTravel to countries with risk or entry requirements.›› Contraindicated if CD4 < 200 cells/µL or AIDS-defining conditions; if CD4 200–499 cells/µL, the decision must be individualized on a case-by-case basis; if CD4 ≥ 500 cells/µL, the vaccine can be administered [19].›› Refer to the current guidelines for all other contraindications [3, 19].Typhoid vaccine (inactivated Vi polysaccharide)RecommendedTravel to high-risk areas, destinations with poor food hygiene.Typhoid vaccine (oral live-attenuated, Ty21a)Conditionally recommendedDepending on local availability, the oral vaccine is preferred if CD4 count ≥ 200 cells/µL (≥ 15%) but contraindicated if CD4 count < 200 cells/µL (< 15%) [3].Cholera vaccine (oral inactivated)Conditionally recommended, no strong dataTravel into areas with ongoing cholera transmission.›› Oral inactivated vaccine may be used may be used in people living with HIV who have CD4 > 200 cells/µL and require cholera protection for travel [23, 24].Cholera vaccine (oral live attenuated)Conditionally recommended, no strong dataTravel into areas with ongoing cholera transmission.›› Live attenuated vaccine is contraindicated in immunosuppressed individuals [23].Ebola vaccineConditionally recommended,no strong dataOccupational exposure in Ebola outbreaks.›› Ad26.ZEBOV, MVA-BN-Filo regimen is supported by clinical trial data for use in HIV-positive adults with well-controlled infection [25], while the rVSV-ZEBOV vaccine may be considered for those at high risk, but with individualized risk assessment due to limited safety data in immunocompromised hosts [19, 26].Japanese encephalitis vaccine (inactivated vaccine)Conditionally recommended,no strong dataTravelers with extended stays in endemic areas, rural/agricultural exposure, transmission season.›› JE-VC (IXIARO) can be administered safely to immunocompromised individuals, including those with HIV, but the immune response may be diminished, especially in those with advanced immunosuppression or low CD4 counts [19, 27].Japanese encephalitis vaccine (live-attenuated vaccines)ContraindicatedUse inactivated Japanese encephalitis vaccine if indicated.Tick-borne encephalitis vaccineConditionally recommendedTravel to endemic areas.›› Vaccination for tick-borne encephalitis is safe for people living with HIV.›› Reduced immunogenicity compared to healthy controls›› Suboptimal early protection with the rapid regimen [28, 29].Chikungunya vaccine (non-replicating virus-like particle – VLP – vaccine)Conditionally recommendedTravel to areas of exposure.›› A VLP-based Chikungunya vaccine is not contraindicated for immunocompromised populations and has demonstrated a favorable safety and immunogenicity profile, with seroresponse rates exceeding 96% and no increase in serious adverse events [30, 31].Chikungunya vaccine (live-attenuated)ContraindicatedUse VLP-based Chikungunya vaccine if indicated.Dengue vaccine (live -attenuated)Conditionally recommendedTravel to dengue-endemic areas in selected individuals.AIDS = acquired immunodeficiency syndrome; ACWY = meningococcal serogroups A, C, W, Y; Ad26.ZEBOV = adenovirus serotype 26–vectored Ebola vaccine; anti-HBs = antibody to hepatitis B surface antigen; CD4 = cluster of differentiation 4 T lymphocytes; COVID-19 = coronavirus disease 2019; DTaP = diphtheria, tetanus, acellular pertussis; HAV = hepatitis A virus; HAV IgG = hepatitis A virus immunoglobulin G; HBs = hepatitis B surface antigen; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; HPV = human papillomavirus; IgG = immunoglobulin G; JE-VC = Japanese encephalitis vaccine, Vero cell–derived; MenACWY = meningococcal conjugate vaccine against serogroups A, C, W, Y; MenB = meningococcal serogroup B vaccine; MMR = measles, mumps, rubella; MVA-BN = modified vaccinia Ankara–Bavarian Nordic; MVA-BN-Filo = modified vaccinia Ankara–Bavarian Nordic filovirus vaccine; PEP = post-exposure prophylaxis; RSV = respiratory syncytial virus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Td = tetanus, diphtheria; Tdap = tetanus, diphtheria, acellular pertussis; Ty21a = live-attenuated Salmonella Typhi Ty21a strain; Vi = Vi capsular polysaccharide antigen; VLP = virus-like particle; VZV = varicella-zoster virus Table 1Vaccines and their recommendation for travelers living with HIV [3, 19, 20]VaccineRecommendationRelevance for travel and special commentsA. Vaccines included in routine vaccination schedulesHepatitis B vaccineRecommendedTravel associated with sexual risk, medical procedures, occupational exposure.›› Check immunization history and anti-HBs levels for those who have been previously vaccinated.›› Check anti-HBs at least 4 weeks after completion of the regimen to confirm optimal response (≥ 10 mIU/mL) [3, 19].Hepatitis A vaccineRecommendedTravel to endemic regions, destinations with poor food hygiene, anticipated at-risk sexual activity.›› Check immunization history and HAV IgG levels for those who have been previously vaccinated.›› Check HAV IgG antibodies at least 4 weeks after completion of the regimen to confirm optimal response [19].MMR vaccineConditionally recommendedTravel to areas with measles outbreaks, or regions with high transmission.›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL.›› Check immunization history and measles (± mumps, ±rubella) IgG levels for those who have been previously vaccinated.COVID-19 vaccineRecommendedExposure in crowded areas/airports. Travel during periods of increased SARS-CoV-2 circulation. Association of risk factors for severe forms.Influenza vaccine (inactivated or recombinant)RecommendedTravel during influenza season. Exposure in crowded places/airports.Influenza vaccine (live-attenuated)ContraindicatedUse inactivated or recombinant influenza vaccine instead.RSV vaccineRecommendedTravel during RSV season for the elderly and/or those at increased risk of severe RSV infection.›› Age limit may vary depending on local vaccine approval.Pneumococcal vaccine (conjugate / polysaccharide)RecommendedHIV is a risk factor for severe pneumococcal disease, and represents an indication for vaccination.Hib vaccineConditionally recommendedTravel by people with chronic conditions with increased risk for Hib infection (asplenia, complement deficiency, immunosuppression, etc.).›› Not routinely recommended for HIV patients but applies to those with additional risk factors.Tetanus, diphtheria, and pertussis vaccine (DTaP, Td, Tdap)RecommendedTravelers at high risk of wounds/trauma.Travelers to areas with risk of diphtheria.Travelers to areas with pertussis outbreaks.›› For those already vaccinated, a previous dose administered within the last 10 years is generally still considered protective.Polio vaccine (inactivated)RecommendedTravel to countries with risk for polio or entry requirements.›› A booster dose administered during adulthood needed for those previously vaccinated during childhood.Meningococcal ACWY vaccine (MenACWY)RecommendedTravel to endemic areas of the “meningitis belt”, meningitis outbreaks or study travel. Travel by people with chronic conditions with an increased risk of meningococcal infection (see Hib).Meningococcal B vaccine (MenB)RecommendedTravel to meningococcal B infection outbreaks.Travel by people with chronic conditions with increased risk for meningococcal infection (see Hib).Varicella vaccineConditionally recommendedTravel to areas with chickenpox outbreaks, regions with transmission or prolonged community exposure.›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL.›› Varicella zoster-specific immunoglobulin can be used in people living with HIV who have contraindication to vaccination, following exposure to VZV [2].›› Check immunization history and varicella-zoster virus IgG levels for those who have been previously vaccinated.Zoster recombinant vaccineRecommendedEveryone 50 years or older; younger people living with HIV and a degree of immunosuppression.HPV vaccineRecommendedLong-term prevention. Recommended regardless of biological sex and especially for sexually active individuals.›› Recommended for persons aged 9–26 years. For selected people aged 27–45 who are inadequately vaccinated, shared clinical decision-making is recommended [19].Mpox vaccineRecommendedTravel to areas with transmission or anticipated exposure.›› Only the JYNNEOS (MVA-BN) vaccine is approved and indicated for people living with HIV regardless of their immune status.B. Travel-specific vaccinesRabies vaccineRecommendedTravel to endemic areas. Exposure to wild animals.›› Post-exposure prophylaxis (PEP) in unvaccinated individuals should include wound cleaning, human rabies immunoglobulin if needed, and a 4-dose vaccine schedule if CD4 ≥ 200 cells/µL or a 5-dose schedule if CD4 < 200 cells/µL or detectable viremia.Yellow fever vaccineConditionally recommendedTravel to countries with risk or entry requirements.›› Contraindicated if CD4 < 200 cells/µL or AIDS-defining conditions; if CD4 200–499 cells/µL, the decision must be individualized on a case-by-case basis; if CD4 ≥ 500 cells/µL, the vaccine can be administered [19].›› Refer to the current guidelines for all other contraindications [3, 19].Typhoid vaccine (inactivated Vi polysaccharide)RecommendedTravel to high-risk areas, destinations with poor food hygiene.Typhoid vaccine (oral live-attenuated, Ty21a)Conditionally recommendedDepending on local availability, the oral vaccine is preferred if CD4 count ≥ 200 cells/µL (≥ 15%) but contraindicated if CD4 count < 200 cells/µL (< 15%) [3].Cholera vaccine (oral inactivated)Conditionally recommended, no strong dataTravel into areas with ongoing cholera transmission.›› Oral inactivated vaccine may be used may be used in people living with HIV who have CD4 > 200 cells/µL and require cholera protection for travel [23, 24].Cholera vaccine (oral live attenuated)Conditionally recommended, no strong dataTravel into areas with ongoing cholera transmission.›› Live attenuated vaccine is contraindicated in immunosuppressed individuals [23].Ebola vaccineConditionally recommended,no strong dataOccupational exposure in Ebola outbreaks.›› Ad26.ZEBOV, MVA-BN-Filo regimen is supported by clinical trial data for use in HIV-positive adults with well-controlled infection [25], while the rVSV-ZEBOV vaccine may be considered for those at high risk, but with individualized risk assessment due to limited safety data in immunocompromised hosts [19, 26].Japanese encephalitis vaccine (inactivated vaccine)Conditionally recommended,no strong dataTravelers with extended stays in endemic areas, rural/agricultural exposure, transmission season.›› JE-VC (IXIARO) can be administered safely to immunocompromised individuals, including those with HIV, but the immune response may be diminished, especially in those with advanced immunosuppression or low CD4 counts [19, 27].Japanese encephalitis vaccine (live-attenuated vaccines)ContraindicatedUse inactivated Japanese encephalitis vaccine if indicated.Tick-borne encephalitis vaccineConditionally recommendedTravel to endemic areas.›› Vaccination for tick-borne encephalitis is safe for people living with HIV.›› Reduced immunogenicity compared to healthy controls›› Suboptimal early protection with the rapid regimen [28, 29].Chikungunya vaccine (non-replicating virus-like particle – VLP – vaccine)Conditionally recommendedTravel to areas of exposure.›› A VLP-based Chikungunya vaccine is not contraindicated for immunocompromised populations and has demonstrated a favorable safety and immunogenicity profile, with seroresponse rates exceeding 96% and no increase in serious adverse events [30, 31].Chikungunya vaccine (live-attenuated)ContraindicatedUse VLP-based Chikungunya vaccine if indicated.Dengue vaccine (live -attenuated)Conditionally recommendedTravel to dengue-endemic areas in selected individuals.AIDS = acquired immunodeficiency syndrome; ACWY = meningococcal serogroups A, C, W, Y; Ad26.ZEBOV = adenovirus serotype 26–vectored Ebola vaccine; anti-HBs = antibody to hepatitis B surface antigen; CD4 = cluster of differentiation 4 T lymphocytes; COVID-19 = coronavirus disease 2019; DTaP = diphtheria, tetanus, acellular pertussis; HAV = hepatitis A virus; HAV IgG = hepatitis A virus immunoglobulin G; HBs = hepatitis B surface antigen; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; HPV = human papillomavirus; IgG = immunoglobulin G; JE-VC = Japanese encephalitis vaccine, Vero cell–derived; MenACWY = meningococcal conjugate vaccine against serogroups A, C, W, Y; MenB = meningococcal serogroup B vaccine; MMR = measles, mumps, rubella; MVA-BN = modified vaccinia Ankara–Bavarian Nordic; MVA-BN-Filo = modified vaccinia Ankara–Bavarian Nordic filovirus vaccine; PEP = post-exposure prophylaxis; RSV = respiratory syncytial virus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Td = tetanus, diphtheria; Tdap = tetanus, diphtheria, acellular pertussis; Ty21a = live-attenuated Salmonella Typhi Ty21a strain; Vi = Vi capsular polysaccharide antigen; VLP = virus-like particle; VZV = varicella-zoster virus Vaccines and their recommendation for travelers living with HIV [3, 19, 20] Travel associated with sexual risk, medical procedures, occupational exposure. ›› Check immunization history and anti-HBs levels for those who have been previously vaccinated. ›› Check anti-HBs at least 4 weeks after completion of the regimen to confirm optimal response (≥ 10 mIU/mL) [3, 19]. Travel to endemic regions, destinations with poor food hygiene, anticipated at-risk sexual activity. ›› Check immunization history and HAV IgG levels for those who have been previously vaccinated. ›› Check HAV IgG antibodies at least 4 weeks after completion of the regimen to confirm optimal response [19]. Travel to areas with measles outbreaks, or regions with high transmission. ›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL. ›› Check immunization history and measles (± mumps, ±rubella) IgG levels for those who have been previously vaccinated. Travel during RSV season for the elderly and/or those at increased risk of severe RSV infection. ›› Age limit may vary depending on local vaccine approval. Travel by people with chronic conditions with increased risk for Hib infection (asplenia, complement deficiency, immunosuppression, etc.). ›› Not routinely recommended for HIV patients but applies to those with additional risk factors. Travelers at high risk of wounds/trauma. Travelers to areas with risk of diphtheria. Travelers to areas with pertussis outbreaks. ›› For those already vaccinated, a previous dose administered within the last 10 years is generally still considered protective. Travel to countries with risk for polio or entry requirements. ›› A booster dose administered during adulthood needed for those previously vaccinated during childhood. Travel to meningococcal B infection outbreaks. Travel by people with chronic conditions with increased risk for meningococcal infection (see Hib). Travel to areas with chickenpox outbreaks, regions with transmission or prolonged community exposure. ›› Contraindicated temporarily when CD4% < 15% or CD4 count < 200 cells/µL. ›› Varicella zoster-specific immunoglobulin can be used in people living with HIV who have contraindication to vaccination, following exposure to VZV [2]. ›› Check immunization history and varicella-zoster virus IgG levels for those who have been previously vaccinated. Long-term prevention. Recommended regardless of biological sex and especially for sexually active individuals. ›› Recommended for persons aged 9–26 years. For selected people aged 27–45 who are inadequately vaccinated, shared clinical decision-making is recommended [19]. Travel to areas with transmission or anticipated exposure. ›› Only the JYNNEOS (MVA-BN) vaccine is approved and indicated for people living with HIV regardless of their immune status. Travel to endemic areas. Exposure to wild animals. ›› Post-exposure prophylaxis (PEP) in unvaccinated individuals should include wound cleaning, human rabies immunoglobulin if needed, and a 4-dose vaccine schedule if CD4 ≥ 200 cells/µL or a 5-dose schedule if CD4 < 200 cells/µL or detectable viremia. Travel to countries with risk or entry requirements. ›› Contraindicated if CD4 < 200 cells/µL or AIDS-defining conditions; if CD4 200–499 cells/µL, the decision must be individualized on a case-by-case basis; if CD4 ≥ 500 cells/µL, the vaccine can be administered [19]. ›› Refer to the current guidelines for all other contraindications [3, 19]. Travel into areas with ongoing cholera transmission. ›› Oral inactivated vaccine may be used may be used in people living with HIV who have CD4 > 200 cells/µL and require cholera protection for travel [23, 24]. Travel into areas with ongoing cholera transmission. ›› Live attenuated vaccine is contraindicated in immunosuppressed individuals [23]. Conditionally recommended, no strong data Occupational exposure in Ebola outbreaks. ›› Ad26.ZEBOV, MVA-BN-Filo regimen is supported by clinical trial data for use in HIV-positive adults with well-controlled infection [25], while the rVSV-ZEBOV vaccine may be considered for those at high risk, but with individualized risk assessment due to limited safety data in immunocompromised hosts [19, 26]. Conditionally recommended, no strong data Travelers with extended stays in endemic areas, rural/agricultural exposure, transmission season. ›› JE-VC (IXIARO) can be administered safely to immunocompromised individuals, including those with HIV, but the immune response may be diminished, especially in those with advanced immunosuppression or low CD4 counts [19, 27]. Travel to endemic areas. ›› Vaccination for tick-borne encephalitis is safe for people living with HIV. ›› Reduced immunogenicity compared to healthy controls ›› Suboptimal early protection with the rapid regimen [28, 29]. Travel to areas of exposure. ›› A VLP-based Chikungunya vaccine is not contraindicated for immunocompromised populations and has demonstrated a favorable safety and immunogenicity profile, with seroresponse rates exceeding 96% and no increase in serious adverse events [30, 31]. AIDS = acquired immunodeficiency syndrome; ACWY = meningococcal serogroups A, C, W, Y; Ad26.ZEBOV = adenovirus serotype 26–vectored Ebola vaccine; anti-HBs = antibody to hepatitis B surface antigen; CD4 = cluster of differentiation 4 T lymphocytes; COVID-19 = coronavirus disease 2019; DTaP = diphtheria, tetanus, acellular pertussis; HAV = hepatitis A virus; HAV IgG = hepatitis A virus immunoglobulin G; HBs = hepatitis B surface antigen; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; HPV = human papillomavirus; IgG = immunoglobulin G; JE-VC = Japanese encephalitis vaccine, Vero cell–derived; MenACWY = meningococcal conjugate vaccine against serogroups A, C, W, Y; MenB = meningococcal serogroup B vaccine; MMR = measles, mumps, rubella; MVA-BN = modified vaccinia Ankara–Bavarian Nordic; MVA-BN-Filo = modified vaccinia Ankara–Bavarian Nordic filovirus vaccine; PEP = post-exposure prophylaxis; RSV = respiratory syncytial virus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Td = tetanus, diphtheria; Tdap = tetanus, diphtheria, acellular pertussis; Ty21a = live-attenuated Salmonella Typhi Ty21a strain; Vi = Vi capsular polysaccharide antigen; VLP = virus-like particle; VZV = varicella-zoster virus Malaria prevention for travelers living with HIV Malaria and HIV infection interact bidirectionally, with each infection exacerbating the clinical course of the other. HIV-induced immunosuppression impairs acquired immunity to malaria, resulting in increased frequency, higher parasite density, and greater severity of malaria episodes, especially in individuals with advanced HIV and low CD4 counts (< 350 cells/µL) [32–34]. Acute malaria episodes can transiently increase HIV viral load, potentially accelerating HIV disease progression and increasing the risk of HIV transmission for several weeks after malaria treatment [34]. Pre-travel malaria risk assessment for people living with HIV should be individualized and should take into account the destination-specific transmission intensity, duration and season of travel, exact destinations and complete itinerary, type of accommodation, planned activities, and the traveler’s prior exposure to malaria. Most travelers from non-endemic regions should be considered non-immune, regardless of HIV status. Even individuals originating from malaria-endemic areas may lose partial immunity after prolonged residence in non-endemic settings, and HIV-related immunosuppression may further reduce any residual protection [32]. Even with prior exposure, protection is not complete, immunity is partial and may only decrease severity of disease, and not prevent infection per se. For this reason, malaria prophylaxis is indicated for all travelers if exposure risk exists at destination. Measures to prevent mosquito bites constitute a fundamental component of the prevention of malaria (and several other vector-borne diseases) and are essential for all travelers, including those receiving chemoprophylaxis. These measures include the use of effective insect repellents (with proven active ingredients such as N, N-diethyl-meta-toluamide (DEET) [35], picaridin [36], or for clothing, permethrin), wearing long-sleeved clothing and trousers, sleeping under insecticide-treated bed nets, and ensuring adequate accommodation window and door screening or air conditioning when available [19]. Non-pharmacological interventions are especially important for people living with HIV, as they are independent of immune status and provide protection against other mosquito-borne infections for which no vaccines or prophylactic medications may be available. People living with HIV should receive standard malaria chemoprophylaxis when traveling to endemic areas, as HIV infection itself is not a contraindication to antimalarial preventive therapy [32, 37]. The choice of chemoprophylactic agent should follow general travel medicine principles and be based on destination-specific resistance patterns, safety profile, and tolerability. However, particular attention must be paid to potential drug-drug interactions between antimalarial agents and antiretroviral therapy (Table 2). Several commonly used antimalarial prophylactic medications may interact with antiretroviral drugs through shared metabolic pathways, particularly those involving cytochrome P450 enzymes. Protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and pharmacokinetic boosters such as ritonavir or cobicistat may alter antimalarial drug levels, potentially affecting efficacy or increasing the risk of adverse events [32, 38, 39]. Potential drug-drug interaction between ART and anti-malaria prophylactic agents should always be checked, ideally using validated tools such as the Liverpool HIV Drug interaction Checker [40]. Adherence to both antiretroviral therapy and malaria prophylaxis should be strongly emphasized. Malaria should always be considered in the differential diagnosis of fever in people living with HIV returning from endemic regions, regardless of reported adherence to chemoprophylaxis. Symptoms may occur weeks or months after exposure, and delayed diagnosis can result in severe disease. Early recognition and prompt diagnostic evaluation are essential to reduce morbidity and mortality. Table 2Antimalarial chemoprophylaxis considerations for people living with HIVAntimalarial agentRecommendationKey considerationsInteractions with ARTCommentsAtovaquone–proguanil [19, 32, 41]RecommendedWell tolerated; suitable for short-term and long-term travel.Potential interactions with boosted protease inhibitors and NNRTIs via CYP metabolism.One of the preferred options when no significant drug-drug interactions are expected.Doxycycline [19, 32, 41]RecommendedSafe regardless of immune status; additional protection against some bacterial infections.No clinically significant interactions with ART.Requires strict daily adherence; photosensitivity and gastrointestinal adverse effects may occur.Mefloquine [19, 32, 41]Use with cautionContraindicated in individuals with history of neuropsychiatric disorders [42].Possible interactions with efavirenz, nevirapine and protease inhibitors (especially boosted with ritonavir) [34, 43].Check ART schedule and pregnancy status [44, 45].Consider only when other options are unsuitable.Chloroquine [19, 32, 41]Recommended in limited settings where susceptibility is confirmed.Use only in regions without chloroquine resistance.Potential QT prolongation when combined with certain ARVs.Limited geographical applicability due to widespread resistance.Primaquine [19, 32, 41]Choice of agent is driven by species risk; CDC recommends it for areas with > 90% P. vivax.Mandatory G6PD testing to prevent hemolysis.Potential interactions with ART not fully characterized. Ritonavir boosting may decrease primaquine plasma concentration (clinical relevance for prevention unclear) [28]. Additive toxicity risks: consider overlapping risks such as QT prolongation with certain ARVs, and hematologic vulnerability.Limited data specifically for people living with HIV.Tafenoquine [19, 32, 41]Choice of agent is driven by species risk (P. vivax, P. falciparum).Mandatory G6PD testing to prevent hemolysis. Some neurological side effects possible [46]. Contraindicated in patients with history of psychotic disorders.Major pharmacological interactions not expected, but limited data available for people living with HIV [46].Long-acting analogue of primaquine (more convenient dosing, fewer expected drug-drug interactions, no clinically significant QTc prolongation).Potentially more clinically significant neuropsychiatric adverse effects due to long half-life.Convenient for longer-term stays due to weekly dosing after initial 3-day loading.Not widely available in some regions of the world for malaria chemoprophylaxis.ART = antiretroviral therapy; ARVs = antiretroviral drugs; CDC = Centers for Disease Control and Prevention, USA; CYP = cytochrome P450 enzyme system; G6PD = glucose-6-phosphate dehydrogenase; NNRTI = non-nucleoside reverse transcriptase inhibitors; QT = QT interval on electrocardiogram; QTc = corrected QT interval; PI = protease inhibitor Table 2Antimalarial chemoprophylaxis considerations for people living with HIVAntimalarial agentRecommendationKey considerationsInteractions with ARTCommentsAtovaquone–proguanil [19, 32, 41]RecommendedWell tolerated; suitable for short-term and long-term travel.Potential interactions with boosted protease inhibitors and NNRTIs via CYP metabolism.One of the preferred options when no significant drug-drug interactions are expected.Doxycycline [19, 32, 41]RecommendedSafe regardless of immune status; additional protection against some bacterial infections.No clinically significant interactions with ART.Requires strict daily adherence; photosensitivity and gastrointestinal adverse effects may occur.Mefloquine [19, 32, 41]Use with cautionContraindicated in individuals with history of neuropsychiatric disorders [42].Possible interactions with efavirenz, nevirapine and protease inhibitors (especially boosted with ritonavir) [34, 43].Check ART schedule and pregnancy status [44, 45].Consider only when other options are unsuitable.Chloroquine [19, 32, 41]Recommended in limited settings where susceptibility is confirmed.Use only in regions without chloroquine resistance.Potential QT prolongation when combined with certain ARVs.Limited geographical applicability due to widespread resistance.Primaquine [19, 32, 41]Choice of agent is driven by species risk; CDC recommends it for areas with > 90% P. vivax.Mandatory G6PD testing to prevent hemolysis.Potential interactions with ART not fully characterized. Ritonavir boosting may decrease primaquine plasma concentration (clinical relevance for prevention unclear) [28]. Additive toxicity risks: consider overlapping risks such as QT prolongation with certain ARVs, and hematologic vulnerability.Limited data specifically for people living with HIV.Tafenoquine [19, 32, 41]Choice of agent is driven by species risk (P. vivax, P. falciparum).Mandatory G6PD testing to prevent hemolysis. Some neurological side effects possible [46]. Contraindicated in patients with history of psychotic disorders.Major pharmacological interactions not expected, but limited data available for people living with HIV [46].Long-acting analogue of primaquine (more convenient dosing, fewer expected drug-drug interactions, no clinically significant QTc prolongation).Potentially more clinically significant neuropsychiatric adverse effects due to long half-life.Convenient for longer-term stays due to weekly dosing after initial 3-day loading.Not widely available in some regions of the world for malaria chemoprophylaxis.ART = antiretroviral therapy; ARVs = antiretroviral drugs; CDC = Centers for Disease Control and Prevention, USA; CYP = cytochrome P450 enzyme system; G6PD = glucose-6-phosphate dehydrogenase; NNRTI = non-nucleoside reverse transcriptase inhibitors; QT = QT interval on electrocardiogram; QTc = corrected QT interval; PI = protease inhibitor Antimalarial chemoprophylaxis considerations for people living with HIV Check ART schedule and pregnancy status [44, 45]. Consider only when other options are unsuitable. Long-acting analogue of primaquine (more convenient dosing, fewer expected drug-drug interactions, no clinically significant QTc prolongation). Potentially more clinically significant neuropsychiatric adverse effects due to long half-life. Convenient for longer-term stays due to weekly dosing after initial 3-day loading. Not widely available in some regions of the world for malaria chemoprophylaxis. ART = antiretroviral therapy; ARVs = antiretroviral drugs; CDC = Centers for Disease Control and Prevention, USA; CYP = cytochrome P450 enzyme system; G6PD = glucose-6-phosphate dehydrogenase; NNRTI = non-nucleoside reverse transcriptase inhibitors; QT = QT interval on electrocardiogram; QTc = corrected QT interval; PI = protease inhibitor Sexually transmitted infections while traveling STIs among travelers are not uncommon, particularly when attending festivals or parties, or when engaging in sexual tourism. The risk of acquiring STIs while traveling depends on many factors and varies according to geographical location, sexual preferences, and accessibility of local prevention programs (screening, prophylaxis, therapy, and vaccinations). The most important immunizations against STIs are hepatitis A and hepatitis B vaccinations (or serological controls). Protection against gonorrhea through the four-component meningococcal group B vaccine (4CMenB) has been introduced in the United Kingdom immunization program for those at highest risk, but is not otherwise universally recommended due to small and quick wearing off of the protective effect [47]. Pre-travel consultations should address postexposure doxycycline prophylaxis (doxy-PEP) in case of high-risk sexual contacts, as it has been shown to reduce the incidence of chlamydia and syphilis among transgender women and MSM, and less so among cisgender women. Administration consists of a single dose of 200 mg of doxycycline ideally within 24 h (but no later than 72 h) after condomless sex, with no more than three doses of 200 mg per week in case of repeated contacts [47–49]. However, short-term immediate benefits of doxy-PEP should be balanced against the long-term risk of selecting for antimicrobial resistance in resident bacterial flora, which has been repeatedly signaled as an emerging concern and has recently led the European Center for Disease Prevention and Control to recommend against routine doxy-PEP as population-level intervention [50]. The prescription of HIV pre- and post-exposure prophylaxis should also be discussed with people living with HIV, as they may be a first resource informing their partners. While people on effective ART with undetectable viral loads do not transmit HIV during unprotected sex, this may no longer apply should ART be stopped or taken irregularly. The increasing resistance of some infectious agents, such as Neisseria gonorrhoeae, and the frequent absence of symptoms complicate the generalizability of STI treatment recommendations for travelers [51]. In the Asian region in particular, the rate of multidrug-resistant bacteria is increasing and cases of Neisseria gonorrhoeae resistant to ceftriaxone have been reported. Referring to local specialists for genitourinary symptoms consultation is essential for accessing adequate antibiotic prescriptions. From an infectious disease point of view, diagnosis should always precede antibiotics prescription, and this is also the case for STIs. Unfortunately, testing availability varies greatly depending on the travel destination, and private services can be expensive. In cases of urethritis and similar conditions, diagnosis can inform the treatment, but it is also necessary to rule out other pathogens or dangerous variants, such as lymphogranuloma venereum (LGV)-serotype Chlamydia, which requires longer treatment [52]. Testfinder.info provides addresses of testing centers across Europe. After STI treatment, especially during travelling, it is necessary to perform adequate follow-up. Depending on national guidelines a test of cure for Chlamydia infections or adequate serological follow-up in relation to syphilis should be performed [53, 54]. When it comes to treating an STI while travelling, there are several factors to consider. First, the local health system may have different standards to those the traveler is accustomed, and access to the system may be difficult for both travelers and locals. Patients may have to pay for testing and treatment, which can be quite costly and unexpected. Another obstacle is the shame and stigma surrounding sex and related topics, which varies greatly between different cultures and travelers. In addition, standard therapies differ significantly between specific guidelines but usually remain the same for people living with HIV as for the general population. As already mentioned, photosensitivity is a possible side effect of doxycycline, which can be problematic in sunny destinations. Alcohol consumption should be avoided, especially while metronidazole is administrated [55]. Atypical presentations and pathogens can be expected as causative factor for STIs during travel, especially for tropical destinations. One example is the dermatophyte Trichophyton mentagrophytes type VII, which causes tinea pubogenitalis, and is particularly prevalent among patients returning from Southeast Asia. It is usually resistant to terbinafine and requires prolonged antifungal treatment [56]. Another important consideration is the spread of enteric pathogens through sexual contacts, especially oral-anal contacts, such as amebiasis and other parasitic infections [57, 58]. Another problem related to travelling is the variable acceptance of different sexual preferences, and the possible stigma and prejudice experienced by minorities and the LGBTQIA+ community, especially gay, bisexual and other MSM. Carrying antiretroviral pills for HIV PrEP or therapy in the luggage can lead to discomfort at border controls. It is important to research for LGBT-friendly countries and areas before the travel (e.g., https://database.ilga.org/en, https://www.positivedestinations.info/). Conclusions International travel is both feasible and increasingly common for people living with HIV in the era of effective ART, but it remains a clinical scenario in which preventable morbidity can occur if HIV-specific considerations are overlooked. This manuscript highlights that safe travel is not achieved solely through viral suppression but requires a structured pre-travel assessment that integrates immunological status, comorbidities, itinerary-specific infectious risks, vaccination planning, and medication logistics into a coherent individualized strategy. Clinical practice should therefore remain mindful of several interconnected domains. First, clinicians should proactively address the practical and pharmacological challenged of travel, including ensuring sufficient ART supply, preventing treatment interruptions, providing clear guidance on time-zone changes, and anticipating potential drug-drug interactions (notably with malaria chemoprophylaxis and commonly prescribed antimicrobials). Second, vaccination planning must go beyond routine recommendations and should incorporate full immunization history, evaluation of immune status, and serological confirmation or boosters when feasible. Third, travel medicine for people living with HIV must explicitly incorporate broader structural and behavioral realities, including potential HIV-related travel restrictions, stigma and disclosure concerns. Finally, travel may be associated with increased likelihood of sexual risk-taking and STI acquisition while abroad, highlighting the importance of access to testing, combined prevention tools, and appropriate treatment in destination settings. A comprehensive approach that includes sexual health counseling is therefore essential. Taken together, the considerations outlined in this article support the view that HIV-informed travel counseling should be regarded as a standard component of longitudinal HIV care rather than an optional add-on. When clinicians adopt a systematic, anticipatory approach grounded in individualized risk assessment and practical planning, travel can be undertaken safely while minimizing avoidable complications, preserving treatment efficacy, and supporting the autonomy and quality of life of people living with HIV.